The Yale Study
In August 2011, Medtronic commissioned Yale University to conduct an independent review of data related to INFUSE® Bone Graft. Click on the links to understand how the Yale study was conducted, its findings on the safety and effectiveness of INFUSE® Bone Graft, and key elements of the review.
The review process
Yale assembled experts from Oregon Health & Sciences University (OHSU) and University of York in the United Kingdom (York) to conduct separate analyses of the data. Learn about the data that were reviewed and the resulting Yale Open Data Access Program (YODA), which makes the data available to other researchers.
Key findings
The Yale study added to the growing body of evidence that INFUSE® Bone Graft is a safe and effective bone graft treatment when used as indicated. The study included a review of key elements such as fusion rates and adverse events.
Medtronic’s perspective
Find more information on Medtronic's position on the Yale analyses. This includes a discussion of topics such as the equivalence of INFUSE® Bone Graft with iliac crest bone graft, ongoing efforts regarding patient safety, how clinical trials were conducted and how consultants reported their research.
Moving forward with rhBMP-2
Learn more about Medtronic's ongoing commitment to data on recombinant human bone morphogenetic protein-2 (rhBMP-2), including the Yale analyses, and plans to expand these data, as well as future applications of INFUSE® Bone Graft.
Have additional safety questions?
For further questions or informational needs:
Contact us
The Yale StudyIn August 2011, Medtronic commissioned Yale University to conduct an independent review of data related to INFUSE® Bone Graft. Click on the links to understand how the Yale study was conducted, its findings on the safety and effectiveness of INFUSE® Bone Graft, and key elements of the review.The review processYale assembled experts from Oregon Health & Sciences University (OHSU) and University of York in the United Kingdom (York) to conduct separate analyses of the data. Learn about the data that were reviewed and the resulting Yale Open Data Access Program (YODA), which makes the data available to other researchers.Key findingsThe Yale study added to the growing body of evidence that INFUSE® Bone Graft is a safe and effective bone graft treatment when used as indicated. The study included a review of key elements such as fusion rates and adverse events.Medtronic’s perspectiveFind more information on Medtronic's position on the Yale analyses. This includes a discussion of topics such as the equivalence of INFUSE® Bone Graft with iliac crest bone graft, ongoing efforts regarding patient safety, how clinical trials were conducted and how consultants reported their research.Moving forward with rhBMP-2Learn more about Medtronic's ongoing commitment to data on recombinant human bone morphogenetic protein-2 (rhBMP-2), including the Yale analyses, and plans to expand these data, as well as future applications of INFUSE® Bone Graft.Have additional safety questions?For further questions or informational needs:Contact us
การแปล กรุณารอสักครู่..